2018 New York City Viral Hepatitis Research Symposium
Equity in Prevention & Treatment
Wednesday May 24, 2018 | Rockefeller University – New York, NY
A successful Viral Hepatitis Research Symposium took place on May 24, 2018 at Rockefeller University. This event brought together more than 200 local medical providers, laboratory directors, community service providers, policy-makers and other stakeholders, and DOHMH staff to review current research and best practices. This event focused on equity in prevention and treatment and focused on priority populations, including recent immigrants, people who inject drugs, and justice-involved, homeless and pregnant individuals. It was an opportunity to showcase local research and innovative projects related to viral hepatitis prevention, management and treatment.
This year’s theme elevated prevention & treatment among priority populations, which includes: recent immigrants, people who inject drugs, justice involved, undocumented, uninsured and pregnant individuals. Attendees came away with a better understanding of current strides towards health equity, the gaps that exist in our knowledge base, and are able to identify future research priorities and interventions.
Program (including Abstracts) here.
Featured speakers included
- Mary Bassett, MD MPH – NYC Commissioner of Health
- Corinna Dan, RN MPH – Viral Hep Policy Advisor HHS
- Ira Jacobson, MD – Dir. of Hepatology NYU Langone Health
- Mark Sulkowski, MD – Med. Director, Viral Hep Center, Johns Hopkins
- Navin Vij, MD – 2018 Symposium Hep C Keynote Speaker. More info.
- Su Wang, MD – 2018 Symposium Hep B Keynote Speaker. More info.
Presentations (update in progress).
- Viral Hepatitis in New York City: Inequity and Priority Populations
Ann Winters, MD | Medical Director, Viral Hepatitis Program. View presentation here.
Hepatitis B Keynote
- HBV | Are We on the Path to Elimination?
Su Wang, MD, MPH |Medical Director, Center for Asian Health. View presentation here.
Overcoming Barriers to Improve HCV Screening. Linkage to Care, and Treatment
- Clinical Outcomes Improvement Following Implementation of HCV Reflex Testing
Dr. Yitz Goldstein, MD, Montefiore Medical Center. View presentation here.
- Hepatitis C Screening Rates in a Large Urban Underserved Academic Center’s Resident Practice
Sadat Iqbal, MD, Kings County Hospital | New York City Health + Hospitals. View presentation here.
- Project INSPIRE: Expanding Care and Providing Support
Marie P. Bresnahan, MPH, New York City Department of Health and Mental Hygiene. View presentation here.
- Project Inspire in the Bronx, an Interdisciplinary Approach to Improve Hepatitis C Cure Rates
Ginger Wey, MD, Montefiore Medical Center. View presentation here.
Epidemiology and Treatment of HBV Among Pregnant Individuals
- Evaluation of Pregnancy Status in Reports of Hepatitis B Submitted by Clinical Laboratories, New York City, Dates: 2014-2017
Ariba Hashmi, MPH, CPH, New York City Department of Health and Mental Hygiene. View presentation here.
- Treatment of HBV Among Pregnant Individuals
Tatyana Kushner, MD, MSCE, Icahn School of Medicine at Mount Sinai. View presentation here.
VIRAL HEPATITIS POLICY PLENARY
Reaching Viral Hepatitis Elimination Requires Federal and Local Action
- National Viral Hepatitis Action Plan: A Framework for Progress
Corinna Dan, RN, MPH |Viral Hepatitis Policy Advisor, United States Department of Health and Human Services. View presentation here.
HCV Among People Who Inject Drugs, and Homeless and Justice-Involved Individuals
- Injection Risk Behaviors and HCV infection among Young Opioid Injectors in New York City: A Challenge to HCV Elimination
Pedro Mateu-Gelabert, PhD, National Development and Research Institutes, Inc. View Presentation here.
- Effect of Direct Acting Antivirals on Health-Related Quality of Life in Patients who Inject Drugs
Samuel C Muench, MD, Montefiore Medical Center. View Presentation here.
- Implementation and Evaluation of a Care Coordination Program for Patients with Hepatitis C Following Release from the New York City Jails
Matthew Akiyama, MD, MSc, Montefiore Medical Center. View Presentation here.
Epidemiology and Treatment of HBV and HCV Among NYC Immigrants and People of Color
- Late Presenters among Minority Patients with Chronic Hepatitis C Infection
Charles Rabinovich, Quality Specialty Pharmacy. View presentation here.
- Challenges and Opportunities for the Elimination of HCV and HBV Infection in Special Populations
Mark Sulkowski, MD | Professor of Medicine, Johns Hopkins University. View presentation here.
1. Describe the latest viral hepatitis research related to special populations including: recent immigrants, people who inject drugs, justice involved, undocumented, uninsured and pregnant individuals.
2. Identify best practices for increasing screening, linkage to care and treatment among special populations.
3. Discuss updates to the evidence base for effective viral hepatitis policy development.
4. Describe research strategies related to viral hepatitis prevention, intervention and treatment to improve the outcomes for special populations.
CME: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Centers for Disease Control and Prevention and New York City Department of Health & Mental Hygiene. The Centers for Disease Control and Prevention is accredited by the (ACCME®) to provide medical education for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Centers for Disease Control and Prevention designates this enduring material for a maximum of 6.0 AMA PRA Category 1 Credits™.
CNE: The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center’s Commission on Accreditation.
This activity provides 6.0 contact hours.
CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.6 CEU’s for this program.
DISCLOSURE: In compliance with continuing education requirements, all presenters must disclose any financial or other associations with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters as well as any use of unlabeled product(s) or product(s) under investigational use.
CDC, our planners, presenters, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters with the exception of Dr. Jacobson who wishes to disclose that he is part of a Speaker’s Bureau for Gilead, Merck & AbbVie and a consultant for AbbVie, BMS, Gilead, Mwerck, Trek, Janssen, Springbank & Assembly Biosciences, Dr. Sulkowski who wishes to disclose that he is a consultant for AbbVie, Gilead, Merck, Trek, Arbutus and was the PI for research grant paid to Johns Hopkins by AbbVie, Gilead, Proteus Digital Health, and Dr. Wang who wishes to disclose that she received research funding from Gilead Sciences under the FOCUS grant. Planning committee reviewed content to ensure there is no bias.
Presentation will not include any discussion of the unlabeled use of a product or a product under investigational use with the exception of Dr. Sulkowski’s discussion on Challenges and opportunities for the elimination of HCV and HBV infection in Special Population. He will be discussing the use of HCV treatment for acute HCV; the potential application of long-acting HCV antivirals.
The Centers for Disease Control and Prevention and New York City Department of Health & Mental Hygiene are jointly providing the CNE for this activity.
CDC did not accept commercial support for this continuing education activity.
Instructions for Obtaining Continuing Education (CE)
In order to receive continuing education (CE) for SP4021 – NYC Viral Hepatitis Research Symposium 2018 please visit TCEO and follow these 9 Simple Steps before June 25, 2018.
FEES: No fees are charged for CDC’s CE activities.